Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
21 October 2021 | Story Xolisa Mnukwa

The University of the Free State (UFS) is currently developing a COVID-19 Regulations and Required Vaccination Policy that all students will have to adhere to in 2022. This policy is being developed to ensure a safe environment for all staff and students upon their return in 2022. 

The university is taking these measures to minimise the risk of exposing staff and students to infection and to enable a safe return to all three UFS campuses next year. However, the university will implement the policy in such a way that it will adequately accommodate individuals who are choosing not to get vaccinated for legitimate reasons.

In order to encourage our students to make the responsible choice by keeping themselves and others safe, the UFS Division of Student Affairs (DSA) is launching a COVID-19 Vaccination Drive that will take place from Monday, 25 October to Wednesday, 27 October 2021.

The programme is as follows:


Monday, 25 October 2021
When: 11:00-14:00
Where: outside Gate 5, UFS Bloemfontein Campus
What: Live performances by students, KovsieFM, KovsieTV, Vox Pops, free UFS branded T-shirts, and giveaways

Wednesday, 27 October 2021
When: 11:00-14:00
Where: Thakaneng Bridge
What: Live performances by local artists and students, KovsieFM, KovsieTV, Vox Pops, free UFS branded T-shirts, and giveaways

COVID-19 Vaccination panel discussion

The Vaccination Drive will conclude on Wednesday, 27 October 2021 with an online panel discussion titled: COVID Vaccination. Informed Youth. Informed Decisions. 
The discussion will start at 16:00 on MS Teams, and students are welcome to join us and ask for advice or clarification about the vaccine from our panel members. The link will be provided soon.

Facilitator: 
Dr Musa Mthombeni, Local TV personality

Panel members include:
Tshepo Moloi, Alumni and Economist representation business sector
Dr Musawenkosi Donia Saurombe, Youngest female PhD holder, lecturer and UFS Alumni
Jerry Thoka, ISRC President
Vusumzi Gqalane, SRC Policy and Transformation on the UFS Vaccination Policy
Asive Dlanjwa, South African Union of Students (SAUS) spokesperson
Victor Sekekete, Free State Cheetahs Rugby Player
Shaxe Khumalo, Entertainment Industry


For more information on the vaccination drive, contact Rethabile Motseki, motsekir@ufs.ac.za or Michelle Nothling at NothlingM@ufs.ac.za 

News Archive

Researchers receive study grant for research into Congo Fever
2015-03-10

UFS researchers will be contributing significantly to the search for a vaccine against the deadly tick-borne disease known as Congo Fever.

Prof Felicity Burt from the Department of Medical Microbiology and Virology was recently awarded a research grant by the National Health Laboratory Service (NHLS) to study candidate vaccines for Crimean-Congo heamorrhagic fever (CCHF) virus and other arboviruses.

Arboviruses are viruses transmitted by mosquitoes, ticks, or other arthropods.

Prof Burt is an internationally-recognised expert on the Crimean-Congo haemorrhagic fever (CCHF). The Crimean-Congo haemorrhagic fever (CCHF) virus is a tick-borne virus that is associated with severe haemorrhagic disease in South Africa and other parts of Africa, Asia, and eastern Europe. Her interests focus on medically significant viruses that are transmitted by ticks and mosquitoes. Her research group is involved in determining the immune responses that are induced by different viral proteins.

Crimean-Congo haemorrhagic fever (CCHF) virus, a tick- borne virus found in Africa, Asia, the Balkans, and eastern Europe, causes severe viral haemorrhagic fever outbreaks.

Although a number of tick species are capable of becoming infected with CCHF virus, ticks of the genus Hyalomma, commonly referred to in SA as the “bont-legged ticks”, are the principal vector. The ticks have distinctive brown and white bands on their legs.

In February 1981, the first case of CCHF was recognised in South Africa (SA). To date, there have been nearly 200 cases of CCHF infection in SA with a 20% fatality rate. The majority of cases occurring in SA were in patients from the Northern Cape and Free State provinces.

“The funding that has been awarded will be used to profile immune responses against CCHF viral proteins, and investigate mechanisms and strategies to enhance these immune responses. We hope that the study will contribute knowledge towards the development of a vaccine against this medically significant virus.”

For more information or enquiries contact news@ufs.ac.za.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept